Teva's Links to Opioid Epidemic May Triple Funding Costs - Bloomberg
America's Most Beloved Pharmaceutical Stock Is Israel's Teva - Bloomberg
HSBC downgrades Teva on uncertainty surrounding DOJ's reported generic drug investigation
Teva Ramps Up Sales With Medis, Respiratory Units - Bloomberg
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Building on Strong First Quarter, Teva Raises 2018 Outlook | Ctech
Teva's $4 Billion Medicine Faces Patent Judgment Day in U.S. - Bloomberg
Teva trades lower after Jefferies cuts rating to Hold | Seeking Alpha
Teva Says 2018 Profit Will Keep Falling as Generic Drug Slump Persists - Bloomberg
Teva's Working With Evercore to Review Debt Options - Bloomberg
Teva Pays $420 Million to End Generic-Drug Securities Suit (1)
Teva Plunges as U.S. Sales Drop Amid Generic Price Erosion - Bloomberg
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - Bloomberg
Pharma Industry Champion Bloomberg: Generic Drugs Could Be Harmful - The Official Myti-Herbs Online Store
Teva Pharmaceuticals - Wikipedia
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva Earnings: Scale Needs To Pay Off Soon - Bloomberg
Teva CEO Steps Down After Patent Losses, Bribery Settlement; Stock Dives | Stock News & Stock Market Analysis - IBD
Allergan becomes largest shareholder in Teva - Globes
Activist Investor Jana Partners Takes Stake in Teva, Report Says | Ctech
Five Considerations After Teva Pharmaceuticals' Q3 Report (NYSE:TEVA) | Seeking Alpha
